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Abstract
Objective
The aim of this retrospective study was to evaluate the diagnostic value and measure inter-
reader agreement of the pancreaticolienal gap (PLG) in the assessment of imaging features
of pancreatic carcinoma (PC) on contrast-enhanced multi-detector computed tomography
(CE-MDCT).
Materials and Methods
CE-MDCT studies in the portal venous phase were retrospectively reviewed for 66 patients
with PC. The age- and gender-matched control group comprised 103 healthy individuals.
Three radiologists with different levels of experience independently measured the PLG (the
minimum distance of the pancreatic tail to the nearest border of the spleen) in the axial
plane. The interreader agreement of the PLG and the receiver operating characteristic
(ROC) curve was used to calculate the accuracy of the technique.
Results
While the control group (n = 103) showed a median PLG of 3 mm (Range: 0 – 39mm) the
PC patients had a significantly larger PLG of 15mm (Range: 0 – 53mm)(p < 0.0001). A ROC
curve demonstrated a cutoff-value of >12 mm for PC, with a sensitivity of 58.2% (95% CI =
45.5–70.1), specificity of 84.0% (95% CI = 75.6–90.4) and an area under the ROC curve of
0.714 (95% CI = 0.641 to 0.780). The mean interreader agreement showed correlation coef-
ficient r of 0.9159. The extent of the PLG did not correlate with tumor stage but did correlate
with pancreatic density (fatty involution) and age, the density decreased by 4.1 HU and the
PLG increased by 0.8 mm within every 10 y.
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Conclusion
The significant interreader agreement supports the use of the PLG as a characterizing fea-
ture of pancreatic cancer independent of the tumor stage on an axial plane. The increase in
the PLG with age may represent physiological atrophy of the pancreatic tail.
Introduction
Pancreatic carcinoma (PC), which is well known as a highly lethal malignancy and a recalci-
trant cancer, has a 5-y survival rate of 6% [1, 2]. This poor prognosis is mainly due to late clini-
cal presentation. Studies investigating the timeline of PC progression have shown that the
onset of symptoms in PC coincides with surgical unresectability [3, 4]. The only potential cura-
tive therapy for PC at this time is complete surgical resection, but only 20% of PC cases are eli-
gible for resection at the time of diagnosis. There is an urgent need for early detection because
the number of new PC cases in the United States is estimated to double (from 43,000 to
88,000) between 2010 and 2030 [5].
Early detection screening, which utilizes inexpensive and accurate diagnostic tests, is an
effective strategy for improving the survival rate. Recent studies have identified several promis-
ing biomarkers from saliva, blood, stools and pancreatic juice [1]. However, tests that are sen-
sitive or specific enough for clinical use do not yet exist [6].
Multi-detector computed tomography (MDCT) plays a pivotal role in both the initial diag-
nosis and the appropriate staging of PC. The key to influencing prognosis through imaging
studies is the detection of early stage lesions. It has been shown that tumor size at diagnosis is
the single most important prognostic indicator in PC [4, 7, 8]. While the progression of pan-
creatic intraepithelial neoplasia (PanIN), a precursor lesion of PC, to an invasive tumor occurs
in minute lesions (< 10 mm; 5–8 mm), extrapancreatic metastases are observed in the majority
of patients with lesions 1 cm [1, 9]. Even MDCT, with its high special resolution, can only
detect PCs that are 1 cm [1, 10]. Because MDCT lacks the sensitivity to detect small lesions,
90% of PC cases are diagnosed when the lesions are large (>2 cm), and often by then, they
have local extrapancreatic spread [11]. Among PC cases, 10 to 15% are isodense and therefore
occult on MDCT [12, 13]. Therefore, identifying noninvasive imaging signs that raise suspi-
cion of a pancreatic malignancy prior to a visible mass formation is required.
On occasion, even for larger pancreatic lesions, the diagnosis of a pancreatic head tumor,
which accounts for 75% of all pancreatic cancers, is difficult to differentiate from focal or
chronic pancreatitis or metastatic disease. No single imaging criterion can perform this differ-
ential diagnosis with certainty. Malignant imaging features strongly indicating a neoplastic dis-
ease of the pancreatic head, such as a double-duct sign or upstream main pancreatic duct
dilatation, may be observed in cases of focal pancreatitis. Other authors have conducted large
surgical studies to show that in 5% of cases, only pancreatitis is found in the resected speci-
mens that are suspicious for pancreatic head tumors [14]. Further secondary signs of a pancre-
atic mass, such as fullness of the pancreatic head by loss of the lobular appearance of the
pancreatic parenchyma, contour abnormalities and pancreatic tail atrophy, are considered to
be indicators of malignancy even if no elusive mass is detected.
Several studies have demonstrated that surgical ligation of the pancreatic duct leads to sig-
nificant pancreatic atrophy [15–18].
We focused on malignant imaging features on MDCT with an emphasis on pancreatic tail
atrophy leading to a PLG through atrophy of the pancreatic tissue in its longitudinal
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dimension. Therefore, the purpose of this retrospective study was to assess the PLG, a potential
malignant imaging feature of PC, on cross-sectional imaging. In addition, we investigated the
age-dependent shrinking of the pancreas, the fatty atrophy, the interreader agreement of PLG
among radiologists, and the correlation between the PLG and tumor stage.
Materials and Methods
Patients
Institutional Review Board (IRB) was waived (University hospital Bern) due to the retrospec-
tive nature of this study. De-identified anonymised patient data were accessed for this study
during a time period of three month (June to August 2015). The inclusion criteria were as fol-
lows: Preoperative contrast-enhanced multi-detector computed tomography (CE-MDCT) in
the portal venous phase and postoperative confirmation of PC with tumor staging according
to the World Health Organization (WHO) criteria or follow-up/tumor monitoring for patients
with unresectable, histologically proven pancreatic cancer. Patients with splenic alterations,
such as splenomegaly, splenectomy or continuous metastatic disease from the pancreatic tail
to the spleen, were excluded. Patient with pancreatic diseases, such as parenchymal calcifica-
tions post pancreatitis, intraductal concrement in the main pancreatic duct and intraparenchy-
mal cystic lesions, were also excluded.
The initial database search yielded 98 patients, 8 of whom were excluded because of a miss-
ing presurgical CT. Of the remaining 90 patients, 22 without PC were excluded because the
initial diagnosis of pancreatic cancer was not confirmed by a pathological evaluation or the
tumor origin remained unclear (18 patients), cholangiocarcinoma was initially misinterpreted
as pancreatic cancer on diagnostic imaging (2 patients), or pancreatitis was present (2
patients). Of the remaining 68 patients with PC, two were excluded due to metastastic disease
of the spleen by direct tumor invasion. The final cohort included 66 patients. The control
group consisted of 103 age- and gender-matched healthy individuals who were recruited ran-
domly from a population with normal abdominal CTs.
To assess the age-dependent shrinking of the pancreas, we investigated the PLG of 20
healthy term newborn infants on ultrasound to assess the starting point. To analyze the age-
related development of the PLG in the control groups (0–40 y), we investigated the PLG on CT
scans of always 10 individuals with normal pancreases and spleens in the age groups of 0–10 y,
11–20 y, 21–30 y and 31–40 y.
In order to quantify the fatty atrophy of the pancreas the density of the pancreatic tail was
measured in Houndsfield-Units (HU) on non-contrast native axial CT-Images of 1mm slice
thickness. Lower densities representing fattier parenchyma. A ROI was set inside the boarder of
the pancreatic tail (>5mm diameter) avoiding inclusion of widened pancreatic ducts and cysts.
Patients with pancreatic carcinoma located in the pancreatic tail were excluded. Also, patients
with only post contrast images were excluded, due to the serious confounding factor of the dif-
ferent individual and phase-dependent enhancement. A total of 47 patients could be identified
with additional non-contrast images in the carcinoma group (23 patients) and in the control
group (24 patients). Age-matching was performed with averaging the densities per decennial
groups. In addition 14 native CT were found and evaluated in the age group below 40 years
with normal pancreases to analyze the aging process as continuous spectrum between 0 and 90
Years. Patients with age lower than one year old were grouped into the age group 0 years.
Measurement technique
In a pilot study of PLG measurements we examined the differences of axial and coronal mea-
surements. We could demonstrate that the axial measurement is closer to the true 3D
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reformatted closest gap between pancreas and spleen (real truth in 3D mode, syngo-via, sie-
mens germany, reformatted plane along the axis of the pancreatic tail):
PLG measured on axial plane and PLG measured on 3D reformatted plane along the pan-
creatic tail shows significant better correlation coefficient r = 0.901 (95% CI for r = 0.801 to
0.952) compared to PLG measured on coronal plan vs. PLG on reformatted plan with a corre-
lation coefficient r = 0.670 (95%CI for r = 0.408 to 0.830) with a p = 0.0151 (z-statistic compar-
ison of correlation coefficient).
PLG measured on axial plane is an approximated value with an absolute error of 0.95mm
+/- 1.8mm (mean +/- SD) compared to the true reformatted closest gap between pancreas and
spleen on 3D reformatted plane. Measurements of the PLG on coronar plane showed a signifi-
cant higher absolute error of 6.8 mm +/-10.0mm (mean +/- SD) with a p-value of 0.0093 (Wil-
coxon paired rank sum test).
There was no significant difference between the interreader agreement of the PLG measure-
ments conducted on axial plane (correlation coefficient r = 0.8641) compered to those on cor-
onal plane (correlation coefficient r = 0.8670) with a p-value of 0.9731 (z-statistic comparison
of correlation coefficient).
In order to provide a simple way to access the PLG on routine scans for different scan pro-
tocols and post processing procedures we suggest measuring the PLG on axial plane.
Pathologic Analysis
After a tumorectomy, which was generally performed by pancreaticoduodenectomy (Whipple
procedure) or distal pancreatectomy, the resected specimen was reviewed by a gastrointestinal
pathologist. The tumor was graded according to the WHO classification on hematoxylin and
eosin-stained specimens on the basis of the most aggressive features indicative of carcinoma,
such as a haphazard growth pattern or perineural and/or intravascular invasion [19].
For tumor staging, both the CT scans and the pathologic assessment of the resected speci-
men were used to evaluate the local invasion of the tumor to the adjacent soft tissue or the vas-
culature. Diagnostic imaging revealed the presence of any metastasis.
Imaging Technique
As some patients initially presented at peripheral institutions, 26 initial scans in the portal
venous phase with variable slice thicknesses (1- to 5-mm slices) on the axial plane were
imported and analyzed on our institution’s workstations. An additional 65 scans were per-
formed on a dual-source MDCT scanner at our institution (Somatom Definition Flash, Sie-
mens Healthcare, Erlangen, Germany) using our standard abdominal CE-MDCT protocol in
the portal venous phase. Axial 1-mm slices and 5-mm slices were reconstructed. Patients were
imaged after IV administration of 110 ml of an iodinated contrast medium (Ultravist 370,
iopromid, 370 mg l/ml, Bayer Healthcare, Leverkusen, Germany) injected at 2 ml/s. The fol-
lowing scanning parameters were used: pitch, 1.0; rotation time, 0.5 s; 120 reference kVp and
140 reference mAs (carekV and caredose); and scanning delay, 70 s for the portal venous
phase. The single remaining scan was performed on a PET/CT, and therefore, the PLG was
evaluated on unenhanced 5-mm slices for this patient. All scans were reviewed on a PACS
workstation (Picture Archiving and Communication System IDS7; Sectra, Linkoping,
Sweden).
Imaging Interpretation
Three radiologists, a radiologist specialized in abdominal and thoracic imaging with 16 y of
experience, a fellow specializing in body imaging with 10 y of experience and a junior faculty
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radiologist with 2.5 y of body imaging experience, independently reviewed the scans. The PLG
was assessed on the axial plane on the image that yielded the smallest distance between the
very distal end of the pancreatic tail and the closest border of the spleen to the pancreatic tail.
Measurements were recorded on the thinnest axial image reconstruction available, and 90% of
measurements were obtained from images with slice thicknesses between 1 and 2 mm. The
readers independently selected the specific slice on which the PLG showed the smallest
distance.
Statistical Analysis
We recorded patient characteristics, such as age; gender; anatomical localization of the pancre-
atic tumor; tumor staging according to the WHO classification (retrieved from the integrated
patient dossier (i-pdos) clinical information system (KIS), CompuGroup medical (CGM),
Phoenix, version 7.8.0.1.5); and the PLG. The Mann-Whitney test was used to compare the PC
and control groups. Tumor staging was pooled into Stages I and II versus Stages III and IV
(Mann-Whitney test). Within the control group, we analyzed the age-dependent development
of the PLG. To calculate the age-dependent shrinkage, we used a linear curve fitting that
assumed a PLG of 0 mm at birth (pilot study). To analyze the age dependent fatty atrophy of
the pancreas a curve fitting was used on the pancreatic HU. Interreader agreement of the PLG
was evaluated using a Bland-Altman plot for ordinal features. A receiver operating characteris-
tic (ROC) curve was applied to calculate the cutoff gap for PC and the area under the curve to
represent accuracy. Statistical significance was defined as p< 0.05. Statistical analyses were
performed on MedCalc1 Version 7.6.0.0 (MedCalc Software, Mariakerke, Belgium). In addi-
tion, the correlation between location of PC (head, body and tail) and PLG was analyzed using
the Mann-Whitney test
Results
The dataset yielded 66 patients (36 male and 30 female; median ages 66 and 65 y, respectively;
range, 19–88 y).
The PC was localized in the pancreatic head in 46 patients (70%), in the pancreatic body in
8 patients (12%) and in the pancreatic tail in 12 patients (18%). The highest prevalence of PC
was found in the 60–69 y age group. The majority of our cohort was diagnosed when lesions
were already involved in adjacent major blood vessels (63%; Stages III and IV). Extension
beyond the pancreas (Stage II-IV) was found in 97% of the patients. Only one patient (2%) was
diagnosed with a precursor lesion (PanIN II) before it became invasive. The distribution of the
tumor staging of the primary lesion at the initial scan is summarized in Table 1.
While the control group (n = 103) showed a median PLG of 3 mm (Range: 0 – 39mm) the
PC patients had a significantly larger PLG of 15mm (Range: 0 – 53mm)(p < 0.0001) (Fig 1). A
ROC curve demonstrated a cutoff-value of>12 mm for PC, with a sensitivity of 58.2% (95%
CI = 45.5–70.1), specificity of 84.0% (95% CI = 75.6–90.4) and an area under the ROC curve of
0.714 (95% CI = 0.641 to 0.780) (Fig 2). The mean interreader agreement showed correlation
Table 1. Tumor staging of the primary lesion at the initial scan according to UICC (Union for International Cancer Control).
Tumor staging 0 and Ia Ib IIa IIb III IV
N (%) 1 (2) 1 (2) 4 (6) 18 (27) 18 (27) 24 (36)
PLG mean (mm) 5 31.0 15.0 15.0 21.6 24.2
SD (+/-) 0.0 0.0 14.7 14.9 10.7 17.2
doi:10.1371/journal.pone.0166003.t001
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coefficient r of 0.9159 (Table 2). The extent of the PLG did not correlate with tumor stage but
did correlate with the age, the PLG increased by 0.8 mm within every10 y.
PC located in the pancreatic body showed a larger PLG indicative for a larger degree of lon-
gitudinal atrophy (p-value: 0.0926, Table 3) compared to PC located in the pancreatic head.
In the pilot study, the 20 healthy term newborn infants (8 male and 12 female, age: 1 to 28
d) showed a PLG of 0 (Fig 3). Within the newborn and the control groups, we analyzed the
age-dependent development of the PLG. The PLG is age correlated and increases by 0.80 mm
within 10 years (Figs 4 and 5).
Fatty atrophy with aging: There was no significant difference in the density of the pancre-
atic tissue between the carcinoma and the control group: the mean density measured 27.0 HU
+/- 16.7 SD and 27.5 HU +/- 13.8 SD, respectively (p-value = 0.9). The density of the pancreas
decreases with age due to fatty atrophy (Fig 6). At birth the average density equals 56.0 HU+/-
12.7 SD and decreases on average 4.1 HU per 10 years to reach a hypothetical density of 15
HU at the age of 100.
The density of the pancreas (pancreatic tail) correlates significantly to the PLG: the correla-
tion coefficient equals -0.882 (95%CI -0.9718 to -0.5668; p-value = 0.0007).
Fig 1. Patients with PC show a significantly larger PLG compared to the control group. (P: pancreas, S: spleen). A: Control group with
normal pancreases. Patients with pancreatic head carcinoma (B) and pancreatic tail carcinoma (C) show a significantly larger PLG
compared to the control group (PLG > 10 mm).
doi:10.1371/journal.pone.0166003.g001
Fig 2. Cut-off value for carcinoma of > 12 mm; Sensitivity: 58.2 (95% CI = 45.5–70.1), Specificity: 84.0 (95% CI = 75.6–90.4) (Fig 2A). Area
under the ROC curve = 0.714 (95% CI = 0.641 to 0.780) (Fig 2B).
doi:10.1371/journal.pone.0166003.g002
Pancreaticolienal Gap in Pancreatic Cancer on MDCT
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Discussion
Several indirect imaging features on MDCT have been associated with malignancy of the pan-
creas in the absence of a visualized mass, including a double-duct sign, upstream main pancre-
atic duct dilatation, contour abnormalities, loss of lobulation and pancreatic tail atrophy [20–
22]. However, these features are difficult to quantify and lack reproducibility. To the best of
our knowledge, this is the first study to quantify pancreatic tail atrophy by measuring the pan-
creaticolienal gap and to identify a reproducible indirect malignant feature.
Our patient cohort comprised a representative selection of patients with pancreatic carci-
noma. Regarding tumor location, our results are consistent with published data [2], with the
PC localized in the pancreatic head in 46 patients (70%), in the pancreatic body in 8 patients
(12%) and in the pancreatic tail in 12 patients (18%).
Our results show that a PLG larger than 12 mm is associated with pancreatic carcinoma.
Patients without pancreatic carcinoma had a smaller or absent PLG. The significant interrea-
der agreement supports the use of the PLG for characterizing malignant features of pancreatic
cancer on MDCT.
Different studies have investigated the double-duct sign. Sensitivities and specificities of
this sign for PC range from 50–76% and from 63–80%, respectively [23–25]. A pathologic PLG
(>12 mm) delivers a comparable sensitivity of 58.2% (95% CI: 45.5–70.1) and a specificity of
84.0% (95% CI: 75.6–90.4), and the confidence intervals match the range of published sensitiv-
ities and specificities of the double-duct sign. In addition, 58% of patients with a pancreatic
malignancy demonstrate a double-duct sign [26]. Similarly, in our cohort, 42 of 66 patients
with PC (63%) showed a pathologic PLG. The correlation between PC with a double duct and
pathologic PLG is the focus of an ongoing study.
Interestingly, our results show that the PLG is age correlated and is not dependent on
tumor stage. Sato et al. published a study on age-dependent atrophy that stated that atrophy is
most prominent in the pancreatic tail on MR images of the normal adult pancreas. They mea-
sured the anterioposterior diameter in the head, body and tail [27]. In our study, we can con-
firm that the longitudinal diameter of the pancreas also decreases with age. Assuming there is
no PLG at birth (pilot study of 20 healthy term newborn infants), we discovered a longitudinal
atrophy of 0.8 mm in 10 y, leading to a hypothetical shrinkage of 8 mm in 100 y. A decreasing
spleen volume may influence the pancreatolienal gap as well, but it is clear that the increasing
Table 2. The mean interreader agreement for the three readers showed correlation coefficient r of 0.9159.
Interreader correlation Correlation coefficient r 95% Confidence interval p-value
Reader 1 –reader 2 0.8419 0.5796 0.9461
Reader 1- reader 3 0.9329 0.8057 0.9779
Reader 2 –reader 3 0.9729 0.9184 0.9912
Average 0.9159 0.7679 0.9717
doi:10.1371/journal.pone.0166003.t002
Table 3. Correlation of PC location and PLG. Compared to PC in the pancreatic head PC located in the
pancreatic body demonstrated a larger PLG indicative of a higher degree of longitudinal pancreatic atrophy.
Tumor location PLG range p-value
head 16 0–48.5 head vs. body 0.0926
body 23 15–57 body vs. tail 0.0031
tail 1 0–38 head vs. tail 0.0101
doi:10.1371/journal.pone.0166003.t003
Pancreaticolienal Gap in Pancreatic Cancer on MDCT
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gap with aging is well below the 10-mm threshold for PC. The tumor stage is not significantly
correlating with the PLG. There is a tendency toward larger gaps in later stages of PC. How-
ever, smaller primaries are already able to metastasize and upgrade the tumor staging without
substantially obstructing the pancreatic duct and, despite a higher staging classification, do not
show an enlargement of the PLG.
Regarding the tumor location PC located in the pancreatic body showed a larger PLG indic-
ative for a larger degree of longitudinal atrophy (p-value: 0.0926) compared to PC located in
the pancreatic head. The higher degree of longitudinal pancreatic atrophy in PC of the
Fig 3. An investigation of the PLG in 20 healthy term newborn infants showed a PLG of 0 on ultrasound with direct contact of the
pancreatic tail with the splenic border.
doi:10.1371/journal.pone.0166003.g003
Pancreaticolienal Gap in Pancreatic Cancer on MDCT
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pancreatic body compared to those of the pancreatic head could be due to upstream of pancre-
atic enzymes in a high concentration restricted to the pancreatic tail leading to a higher degree
of atrophy.
There is significant difference between the PLG due to tumor located in the pancreatic tail
compared to tumor located in the pancreatic head and body with shorter PLG for tail located
tumors due to direct invasion of the splenic hilus.
Obviously, there is no additional fatty atrophy in the pancreatic tail in carcinoma patients.
It seems that the replacement of pancreatic tissue exists only in aging and not in the relative
fast longitudinal atrophy due to tumor-obstruction. We demonstrated a decennial decrease in
HU of the pancreatic tail of 4.1 HU which is in concordance with previous published studies
[28]. Saisho et al. showed that pancreatic fat increases with aging in both men and women, to a
greater extent in men with the composite effects of decreased parenchymal and increased fat
volume. It correlates significantly with the longitudinal atrophy of the pancreas with aging, but
not with longitudinal atrophy due to pancreatic cancer.
Fig 4. Age-related development of the PLG in the control group. The PLG is age correlated and increases by 0.8 mm within 10 years (P:
pancreas, S: spleen). A: age group 40–50 y. B: age group 50–60 y, C: age group 60–70 y, D: age group 70–80 y, E: age group 80–90 y.
doi:10.1371/journal.pone.0166003.g004
Fig 5. Age-related development of the PLG in the control group. Linear curve fitting demonstrated a good
correlation between the PLG and age (R2 >0.5): The PLG increased by an average of 0.8 mm every 10 years, with a
PLG of 0 mm at birth and a hypothetical gap of 8.6 mm at 100 y.
doi:10.1371/journal.pone.0166003.g005
Pancreaticolienal Gap in Pancreatic Cancer on MDCT
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This study was limited by its retrospective nature. A total of 26 initial scans exhibiting pan-
creatic tumors were performed at peripheral institutions and imported to our workstation
with variable slice thicknesses (1- to 5-mm slices). As all scans performed at our institution
were read at 1-mm slices, the lack of available high-quality, thin-section images from other
institutions may have caused an underestimation of the PLG in these patients. In addition, the
scan protocols varied among different institutions. However, this inconsistency in CT proto-
cols provided us with the possibility of comparing the influence of the enhancement phases of
pancreatic tissue and the spleen on the measurability of the PLG. It is our impression that the
enhancement pattern does not influence the visibility of the splenic border and the pancreatic
tail and, therefore, does not have an impact on the PLG. Further studies on this issue are
needed. In addition, the nonexistent PLG at birth needs to be confirmed in a larger study pop-
ulation. Because of the relatively specific inclusion criteria, the possibility of a selection bias
cannot be ruled out. However, we enrolled a representative selection of patients with pancreas
carcinoma in this study.
In summary, patients with PC show a significantly larger PLG compared to the control
group, with a cutoff of 10 mm. The significant interreader agreement supports the use of PLG
for characterizing malignant features of pancreatic cancer independent of tumor stage on the
axial plane. Our results indicate a promising role for the PLG as an indirect malignant feature
for tumor detection, which has comparable accuracy to the double-duct sign, in patients with
pancreatic tumors. A prospective study to validate the use of the PLG and its added value in
tumor detection is still warranted.
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